Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Internet Enforcement Without Guidance May Create "Incongruity" - Lilly

Executive Summary

FDA's decision to halt work on an Internet guidance could result in enforcement "incongruity," Lilly Associate Internet Consultant Michael Pozsgai told a Drug Information Association conference in Washington D.C. Nov. 3.

You may also be interested in...



CDER Compliance Office Redesign Includes Internet, Risk Management Focus

The FDA Center for Drug Evaluation & Research's reorganized Office of Compliance includes a team focused on illegal sale of OTC and prescription drugs on the Internet

Pharmaceutical Website Links Receiving FDA Scrutiny, Ad Division Says

FDA's advertising division is examining the content of sites to which pharmaceutical product websites provide links.

Pharmaceutical Website Links Receiving FDA Scrutiny, Ad Division Says

FDA's advertising division is examining the content of sites to which pharmaceutical product websites provide links.

Related Content

UsernamePublicRestriction

Register

PS035124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel